ArticleBMC pregnancy and childbirth2025
Transcriptomics-based identification of lysine crotonylation-related biomarkers in pre-eclampsia.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Food Contaminant to Therapeutic Target: Identification of KCNE2 and 5-Azacytidine for Gastric Cancer via Multi-Omics, Machine Learning, and In Vitro Validation.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLysine crotonylation has been implicated in the pathogenesis of preeclampsia (PE). However, the underlying mechanisms remain unclear. This study aimed to identify crotonylation-related biomarkers in PE through bioinformatics analysis.
methodsPublicly available datasets, including GSE48424 and GSE149440, were utilized in this study. Candidate biomarkers were identified by intersecting differentially expressed genes (DEGs) from differential expression analysis with key module genes obtained through weighted gene co-expression network analysis (WGCNA). Biomarkers were further refined using expression analysis and machine learning techniques. Functional analysis, immune infiltration analysis, methylation modifications, and construction of molecular regulatory networks were employed to explore the potential mechanisms underlying the involvement of candidate biomarkers in PE pathogenesis. Additionally, associations between the biomarkers and common clinical predictive molecules were examined, and their diagnostic performance for PE was evaluated.
resultsA total of 323 candidate genes were identified by intersecting 3,353 DEGs with 402 key module genes. Expression analysis and machine learning algorithms pinpointed DPYD and PRDX3 as biomarkers. DPYD and PRDX3 were identified as lysine crotonylation-related biomarkers in PE. These genes were significantly downregulated in PE and associated with pathways such as olfactory signaling, neutrophil degranulation, and immune microenvironment dysregulation. Both biomarkers demonstrated excellent diagnostic efficacy (AUC > 0.85), outperforming traditional markers like VEGFA. Additionally, DPYD and PRDX3 are associated with oxidative stress and immune dysregulation, which may be the key mechanisms for the development of PE.
conclusionThis study identified DPYD and PRDX3 as lysine crotonylation-related biomarkers in PE, providing new insights for the diagnosis and management of the condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.